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Background: Mobile health (mHealth) is the transmission of physiologic data and symptoms of patients at home to providers and has been 
suggested to improve outcomes among HF patients. The current analysis aims to determine the outcomes of telemonitoring and to identify 
specific cohorts of patients and the types of technologies that are effective
methods: A comprehensive literature search was conducted to identify RCTs that compared either wearable mHealth daily monitoring 
devices (weight, BP, oximetry, ECG heart rate/rhythm) or implantable continuous monitoring devices (direct [pressure] or indirect cardiac 
measurements [thoracic impedance]) with usual care in HF patients with reduced or preserved EF. Outcomes of all cause mortality and 
hospitalizations were abstracted. Pooled relative risks (RR) for each outcome by device type (wearable or implantable) were determined by 
random effects meta-analyses
results: 31 RCTs were identified: 25 evaluating wearable devices (n=7,423 patients), 6 evaluating implantable devices (n=3,362 
patients). In meta analyses, wearable devices were associated with decreased mortality [RR (95%CI) =0.76 (0.63, 0.92)] and the risk of 
hospitalizations [0.81 (0.72, 0.91]. Pooled RR’s for all implantable devices showed no significant effect on mortality [1.03 (0.71, 1.48)] or 
hospitalization [0.97 (0.66, 1.43)]. In the 2 trials using implantable devices with direct cardiac measurements, decreases in hospitalization 
were seen [0.70 (0.56, 0.87)]. Wearable device monitoring demonstrated improved outcomes among younger patients (<70 years) and 
reduced hospitalizations at 3 months with sustained benefits on mortality and hospitalizations at 1 year. Whereas, mHealth device use did 
not impact outcomes among older patients or studies that enrolled ambulatory patients as opposed to patients recently hospitalized for HF
conclusion:  Meta analyses of RCTs of telemonitoring in HF patients demonstrate that use of wearable mHealth devices is associated 
improved outcomes. RCTs using implantable devices showed no significant effect on outcomes, but suggest that results may vary by the 
parameter measured, with direct hemodynamic parameters demonstrating the most promise
